Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor

NCT00095706 is registered in ClinicalTrials.gov with Translational Oncology Research International as lead sponsor.

NCT NCT00095706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Lead sponsor
Translational Oncology Research International
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2003
Completion date
January 31, 2012
Enrollment
50 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer